CRIS
Price:
$3.17
Market Cap:
$26.84M
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small mol...[Read more]
Industry
Biotechnology
IPO Date
2000-08-01
Stock Exchange
NASDAQ
Ticker
CRIS
According to Curis, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.25M. This represents a change of -79.54% compared to the average of 45.20M of the last 4 quarters.
The mean historical Enterprise Value of Curis, Inc. over the last ten years is 184.55M. The current 9.25M Enterprise Value has changed 401.02% with respect to the historical average. Over the past ten years (40 quarters), CRIS's Enterprise Value was at its highest in in the December 2017 quarter at 2.30B. The Enterprise Value was at its lowest in in the March 2020 quarter at 11.72M.
Average
184.55M
Median
128.59M
Minimum
34.70M
Maximum
402.80M
Discovering the peaks and valleys of Curis, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 572.44%
Maximum Annual Enterprise Value = 402.80M
Minimum Annual Increase = -90.41%
Minimum Annual Enterprise Value = 34.70M
Year | Enterprise Value | Change |
---|---|---|
2023 | 43.60M | 13.40% |
2022 | 38.45M | -90.41% |
2021 | 400.90M | 44.90% |
2020 | 276.66M | 572.44% |
2019 | 41.14M | 18.57% |
2018 | 34.70M | -67.77% |
2017 | 107.66M | -73.27% |
2016 | 402.80M | 15.06% |
2015 | 350.07M | 134.14% |
2014 | 149.51M | -40.94% |
The current Enterprise Value of Curis, Inc. (CRIS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
160.98M
5-year avg
160.15M
10-year avg
184.55M
Curis, Inc.’s Enterprise Value is less than Aileron Therapeutics, Inc. (29.36M), greater than Artelo Biosciences, Inc. (523.87K), greater than Histogen Inc. (-4487565.00), greater than Timber Pharmaceuticals, Inc. (-7573217.00), less than X4 Pharmaceuticals, Inc. (79.71M), less than Mereo BioPharma Group plc (510.15M), less than Inozyme Pharma, Inc. (210.44M), less than Terns Pharmaceuticals, Inc. (223.81M), less than Leap Therapeutics, Inc. (49.06M), less than Day One Biopharmaceuticals, Inc. (857.57M), less than PDS Biotechnology Corporation (36.27M), less than Adaptimmune Therapeutics plc (55.99M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), less than Affimed N.V. (23.62M), less than Corvus Pharmaceuticals, Inc. (310.53M), less than Aptose Biosciences Inc. (25.60M),
Company | Enterprise Value | Market cap |
---|---|---|
29.36M | $47.02M | |
523.87K | $3.13M | |
-4487565.00 | $85.44K | |
-7573217.00 | $1.18M | |
79.71M | $98.92M | |
510.15M | $589.54M | |
210.44M | $188.22M | |
223.81M | $492.65M | |
49.06M | $111.51M | |
857.57M | $1.28B | |
36.27M | $61.35M | |
55.99M | $148.11M | |
-1407736.00 | $17.96M | |
23.62M | $18.88M | |
310.53M | $314.86M | |
25.60M | $14.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Curis, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Curis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Curis, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Curis, Inc. (CRIS)?
What is the 3-year average Enterprise Value for Curis, Inc. (CRIS)?
What is the 5-year average Enterprise Value for Curis, Inc. (CRIS)?
How does the current Enterprise Value for Curis, Inc. (CRIS) compare to its historical average?